ARTICLE | Company News

Elan, EntreMed deal

July 19, 2004 7:00 AM UTC

ELN's Elan Drug Delivery Inc. unit will reformulate and manufacture an oral liquid version of ENMD's Panzem 2-methoxyestradiol. The formulation of the small molecule inhibitor of angiogenesis and cell proliferation will use ELN's NanoCrystal delivery technology. ENMD plans to start clinical trials of the compound in cancer patients early next year. ...